5-s-cysteinyldopamine has been researched along with Parkinson Disease in 11 studies
*Parkinson Disease: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75) [MeSH]
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (36.36) | 18.2507 |
| 2000's | 2 (18.18) | 29.6817 |
| 2010's | 5 (45.45) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Badillo-Ramírez, I; Rivas-Arancibia, S; Saniger, JM | 1 |
| Aureli, C; Cassano, T; Chichiarelli, S; Cocciolo, A; d'Erme, M; Fontana, M; Francioso, A; Gaetani, S; Mancini, P; Martire, S; Masci, A; Mosca, L; Romano, A | 1 |
| Goldstein, DS; Holmes, C; Jinsmaa, Y; Kopin, IJ; Sharabi, Y; Sullivan, P | 1 |
| Asmaro, K; Beningo, KA; Hermiz, DJ; Mehta, NJ; Njus, D; Njus, MM; Saleh, AH | 1 |
| Corona, G; Spencer, JP; Vauzour, D | 1 |
| Cheng, FC; Chia, LG; Dryhurst, G; Kuo, JS | 1 |
| Dryhurst, G; Li, H; Shen, XM | 2 |
| Dryhurst, G; Li, H | 1 |
| Carlsson, A; Fornstedt, B | 2 |
2 review(s) available for 5-s-cysteinyldopamine and Parkinson Disease
| Article | Year |
|---|---|
5-S-cysteinyl-dopamine, a neurotoxic endogenous metabolite of dopamine: Implications for Parkinson's disease.
Topics: alpha-Synuclein; Biomarkers; Dopamine; Dopaminergic Neurons; Endoplasmic Reticulum Stress; Humans; Metabolic Networks and Pathways; Mitochondria; Nerve Tissue Proteins; Neuroprotective Agents; Oxidation-Reduction; Oxidative Stress; Parkinson Disease; Pars Compacta; Sulfur | 2019 |
Possible mechanisms underlying the special vulnerability of dopaminergic neurons.
Topics: Aged; Aged, 80 and over; Animals; Brain; Cell Survival; Dopamine; Humans; Neurons; Parkinson Disease; Parkinson Disease, Secondary; Receptors, Dopamine | 1991 |
9 other study(ies) available for 5-s-cysteinyldopamine and Parkinson Disease
| Article | Year |
|---|---|
5-S-cysteinyldopamine neurotoxicity: Influence on the expression of α-synuclein and ERp57 in cellular and animal models of Parkinson's disease.
Topics: alpha-Synuclein; Animals; Biogenic Monoamines; Brain; Cell Line, Tumor; Disease Models, Animal; Dopamine; Dopamine Agents; Dose-Response Relationship, Drug; Glutathione; Glutathione Disulfide; Humans; Male; Mice; Neuroblastoma; Oxidative Stress; Oxidopamine; Parkinson Disease; Protein Carbonylation; Protein Disulfide-Isomerases | 2014 |
Elevated cerebrospinal fluid ratios of cysteinyl-dopamine/3,4-dihydroxyphenylacetic acid in parkinsonian synucleinopathies.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aged; Animals; Catechols; Dihydroxyphenylalanine; Dopamine; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Multiple System Atrophy; Parkinson Disease; PC12 Cells; Putamen; Rats | 2016 |
Hypochlorite converts cysteinyl-dopamine into a cytotoxic product: A possible factor in Parkinson's Disease.
Topics: Animals; Cell Survival; Cytotoxins; Dopamine; Humans; Hypochlorous Acid; Models, Biological; Oxidation-Reduction; Oxidative Stress; Parkinson Disease; PC12 Cells; Peroxidase; Rats; Superoxides; Taurine | 2016 |
Caffeic acid, tyrosol and p-coumaric acid are potent inhibitors of 5-S-cysteinyl-dopamine induced neurotoxicity.
Topics: Animals; Caffeic Acids; Cells, Cultured; Coumaric Acids; Dopamine; Flavonoids; Mice; Neurons; Neuroprotective Agents; Parkinson Disease; Phenylethyl Alcohol; Propionates; Wine | 2010 |
Elevated 5-S-cysteinyldopamine/homovanillic acid ratio and reduced homovanillic acid in cerebrospinal fluid: possible markers for and potential insights into the pathoetiology of Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Biomarkers; Chromatography, High Pressure Liquid; Dopamine; Female; Homovanillic Acid; Humans; Levodopa; Male; Parkinson Disease; Reference Values | 1996 |
Brain mitochondria catalyze the oxidation of 7-(2-aminoethyl)-3,4-dihydro-5-hydroxy-2H-1,4-benzothiazine-3-carboxyli c acid (DHBT-1) to intermediates that irreversibly inhibit complex I and scavenge glutathione: potential relevance to the pathogenesis of
Topics: Animals; Brain; Catalysis; Dopamine; Electron Transport Complex I; Enzyme Inhibitors; Free Radical Scavengers; Glutathione; Male; Mitochondria; NAD(P)H Dehydrogenase (Quinone); NADH, NADPH Oxidoreductases; Oxidation-Reduction; Parkinson Disease; Rats; Rats, Sprague-Dawley; Thiazines | 1998 |
Oxidative metabolites of 5-S-cysteinyldopamine inhibit the alpha-ketoglutarate dehydrogenase complex: possible relevance to the pathogenesis of Parkinson's disease.
Topics: Animals; Antioxidants; Brain; Catalase; Dopamine; Electron Transport Complex IV; Enzyme Inhibitors; Intracellular Membranes; Ketoglutarate Dehydrogenase Complex; Male; Mitochondria; Oxidation-Reduction; Parkinson Disease; Prostaglandin-Endoperoxide Synthases; Rats; Rats, Sprague-Dawley; Superoxide Dismutase; Thiazines | 2000 |
Oxidative metabolites of 5-S-cysteinyldopamine inhibit the pyruvate dehydrogenase complex.
Topics: Animals; Ascorbic Acid; Catalase; Dopamine; Energy Metabolism; Glutathione; Intracellular Membranes; Male; Mitochondria; Neurons; Oxidative Stress; Parkinson Disease; Pyruvate Dehydrogenase Complex; Rats; Rats, Sprague-Dawley; Substantia Nigra; Superoxide Dismutase; Thiazines | 2001 |
Catechol metabolites in the cerebrospinal fluid as possible markers in the early diagnosis of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Brain; Catechols; Dopamine; Guinea Pigs; Humans; Oxidation-Reduction; Parkinson Disease; Time Factors | 1991 |